 |
|
|
REFERENCES
1.
Griffith H, Johnson GE: The use of curare in general
anesthesia. Anesthesiology 3:418, 1942.
2.
Cullen SC: The use of curare for improvement of
abdominal relaxation during cyclopropane anesthesia: Report on 131 cases. Surgery
14:216, 1943.
3.
Beecher HK, Todd DP: A study of the deaths associated
with anesthesia and surgery: Based on a study of 599,548 anesthesias in ten institutions
1948–1952, inclusive. Ann Surg 140:2–35, 1954.
4.
Foldes FF, McNall PG, Borrego-Hinojosa JM: Succinylcholine,
a new approach to muscular relaxation in anesthesiology. N Engl J Med 247:596–600,
1952.
5.
Thesleff S: Farmakologisks och kliniska forsok
med L.T. I. (O,O-succinylcholine jodid). Nord Med 46:1045, 1951.
6.
Baird WL, Reid AM: The neuromuscular blocking properties
of a new steroid compound, pancuronium bromide. A pilot study in man. Br J Anaesth
39:775–780, 1967.
7.
Savage DS, Sleigh T, Carlyle I: The emergence of
ORG NC 45,1-[2 beta,3 alpha,5 alpha,16 beta,17 beta-3,17-bis(acetyloxy)-2-(1-piperidinyl)-androstan-16-yl]-1-methylpiperidinium
bromide, from the pancuronium series. Br J Anaesth 52(Suppl 1):3S–9S, 1980.
8.
Stenlake JB, Waigh RD, Dewar GH, et al: Biodegradable
neuromuscular blocking agents. Part 4: Atracurium besylate and related polyalkylylene
di-esters. Eur J Med Chem 16:515, 1981.
9.
Stenlake JB, Waigh RD, Urwin J, et al: Atracurium:
Conception and inception. Br J Anaesth 55(Suppl 1):3S–10S, 1983.
10.
Savarese JJ, Ali HH, Basta SJ, et al: The clinical
neuromuscular pharmacology of mivacurium chloride (BW B1090U). A short-acting nondepolarizing
ester neuromuscular blocking drug. Anesthesiology 68:723–732, 1988.
11.
Wierda JM, de Wit AP, Kuizenga K, et al: Clinical
observations on the neuromuscular blocking action of Org 9426, a new steroidal non-depolarizing
agent. Br J Anaesth 64:521–523, 1990.
12.
Gyermek L: Structure-activity relationships among
derivatives of dicarboxylic acid esters of tropine. Pharmacol Ther 96:1–21,
2002.
13.
Zhu HJ, Sacchetti M: Solid state characterization
of a neuromuscular blocking agent—GW280430A. Int J Pharm 234:19–23,
2002.
14.
On being aware. Br J Anaesth 51:711–712,
1979.
15.
Shovelton DS: Reflections on an intensive therapy
unit. BMJ 1:737–728, 1979.
16.
Cullen SC, Larson CPJ: Essentials of Anesthetic
Practice. Chicago, Year Book, 1974.
17.
Naguib M, Flood P, McArdle JJ, et al: Advances
in neurobiology of the neuromuscular junction: Implications for the anesthesiologist.
Anesthesiology 96:202–231, 2002.
18.
Machold J, Weise C, Utkin Y, et al: The handedness
of the subunit arrangement of the nicotinic acetylcholine receptor from Torpedo
californica. Eur J Biochem 234:427–430, 1995.
19.
Yu XM, Hall ZW: Extracellular domains mediating
epsilon subunit interactions of muscle acetylcholine receptor. Nature 352:64–67,
1991.
20.
Willcockson IU, Hong A, Whisenant RP, et al: Orientation
of d-tubocurarine in the muscle nicotinic acetylcholine
receptor-binding site. J Biol Chem 277:42249–42258, 2002.
21.
Neubig RR, Cohen JB: Equilibrium binding of [3
H]tubocurarine
and [3
H]acetylcholine by Torpedo postsynaptic
membranes: Stoichiometry and ligand interactions. Biochemistry 18:5464–5475,
1979.
22.
Villarroel A, Sakmann B: Calcium permeability
increase of endplate channels in rat muscle during postnatal development. J Physiol
(Lond) 496:331–338, 1996.
23.
Sine SM, Claudio T, Sigworth FJ: Activation of
Torpedo acetylcholine receptors expressed in mouse
fibroblasts. Single channel current kinetics reveal distinct agonist binding affinities.
J Gen Physiol 96:395–437, 1990.
24.
Devillers-Thiery A, Galzi JL, Eisele JL, et al:
Functional architecture of the nicotinic acetylcholine receptor: A prototype of
ligand-gated ion channels. J Membr Biol 136:97–112, 1993.
25.
Grosman C, Zhou M, Auerbach A: Mapping the conformational
wave of acetylcholine receptor channel gating. Nature 403:773–776, 2000.
26.
Grosman C, Salamone FN, Sine SM, et al: The extracellular
linker of muscle acetylcholine receptor channels is a gating control element. J
Gen Physiol 116:327–340, 2000.
27.
Bowman WC: Pharmacology of Neuromuscular Function,
2nd ed. London, Wright, 1990.
28.
Paul M, Kindler CH, Fokt RM, et al: The potency
of new muscle relaxants on recombinant muscle-type acetylcholine receptors. Anesth
Analg 94:597–603, 2002.
29.
Rosenberry TL: Acetylcholinesterase. Adv Enzymol
Relat Areas Mol Biol 43:103–218, 1975.
30.
Martyn JA: Basic and clinical pharmacology of
the acetylcholine receptor: Implications for the use of neuromuscular relaxants.
Keio J Med 44:1–8, 1995.
31.
Kallen RG, Sheng ZH, Yang J, et al: Primary structure
and expression of a sodium channel characteristic of denervated and immature rat
skeletal muscle. Neuron 4:233–242, 1990.
32.
Bowman WC: Prejunctional and postjunctional cholinoceptors
at the neuromuscular junction. Anesth Analg 59:935–943, 1980.
33.
Prior C, Tian L, Dempster J, et al: Prejunctional
actions of muscle relaxants: Synaptic vesicles and transmitter mobilization as sites
of action. Gen Pharmacol 26:659–666, 1995.
34.
Wessler I, Diener A, Offermann M: Facilitatory
and inhibitory muscarine receptors on the rat phrenic nerve: Effects of pirenzepine
and dicyclomine. Naunyn Schmiedebergs Arch Pharmacol 338:138–142, 1988.
35.
Starke K, Gothert M, Kilbinger H: Modulation of
neurotransmitter release by presynaptic autoreceptors. Physiol Rev 69:864–989,
1989.
36.
Slutsky I, Silman I, Parnas I, et al: Presynaptic
M(2) muscarinic receptors are involved in controlling the kinetics of ACh release
at the frog neuromuscular junction. J Physiol 536:717–725, 2001.
37.
Slutsky I, Parnas H, Parnas I: Presynaptic effects
of muscarine on ACh release at the frog neuromuscular junction. J Physiol 514(Pt
3):769–782, 1999.
38.
Slutsky I, Wess J, Gomeza J, et al: Use of knockout
mice reveals involvement of M2-muscarinic receptors in control of the kinetics of
acetylcholine release. J Neurophysiol 89:1954–1967, 2003.
39.
Bowman WC, Prior C, Marshall IG: Presynaptic receptors
in the neuromuscular junction. Ann N Y Acad Sci 604:69–81, 1990.
40.
Churchill-Davidson HC, Christie TH: Diagnosis
of neuromuscular block in man. Br J Anaesth 31:290–295, 1959.
41.
Christie TH, Churchill-Davidson HC: St. Thomas'
Hospital nerve stimulator in diagnosis of prolonged apnea. Lancet 1:776–778,
1958.
42.
Brull SJ, Connelly NR, O'Connor TZ, et al: Effect
of tetanus on subsequent neuromuscular monitoring in patients receiving vecuronium.
Anesthesiology 74:64–70, 1991.
43.
Viby-Mogensen J, Howardy-Hansen P, Chraemmer-Jorgensen
B, et al: Posttetanic count (PTC): A new method of evaluating an intense nondepolarizing
neuromuscular blockade. Anesthesiology 55:458–461, 1981.
44.
Kim SY, Lee JS, Kim SC, et al: Twitch augmentation
and train-of-four fade during onset of neuromuscular block after subclinical doses
of suxamethonium. Br J Anaesth 79:379–381, 1997.
45.
Naguib M: Are fade and sustained post-tetanic
facilitation characteristics of typical succinylcholine-induced block? Br J Anaesth
87:522–524, 2001.
46.
Donati F, Meistelman C, Plaud B: Vecuronium neuromuscular
blockade at the adductor muscles of the larynx and adductor pollicis. Anesthesiology
74:833–837, 1991.
47.
Pansard JL, Chauvin M, Lebrault C, et al: Effect
of an intubating dose of succinylcholine and atracurium on the diaphragm and the
adductor pollicis muscle in humans. Anesthesiology 67:326–330, 1987.
48.
Waud BE, Waud DR: The relation between tetanic
fade and receptor occlusion in the presence of competitive neuromuscular block.
Anesthesiology 35:456–464, 1971.
49.
Kopman AF: Tactile evaluation of train-of-four
count as an indicator of reliability of antagonism of vecuronium- or atracurium-induced
neuromuscular blockade. Anesthesiology 75:588–593, 1991.
50.
Engbaek J, Ostergaard D, Viby-Mogensen J: Double
burst stimulation (DBS): A new pattern of nerve stimulation to identify residual
neuromuscular block. Br J Anaesth 62:274–278, 1989.
51.
Connelly NR, Silverman DG, O'Connor TZ, et al:
Subjective responses to train-of-four and double burst stimulation in awake patients.
Anesth Analg 70:650–653, 1990.
52.
Drenck NE, Ueda N, Olsen NV, et al: Manual evaluation
of residual curarization using double burst stimulation: A comparison with train-of-four.
Anesthesiology 70:578–581, 1989.
53.
Pavlin EG, Holle RH, Schoene RB: Recovery of airway
protection compared with ventilation in humans after paralysis with curare. Anesthesiology
70:381–385, 1989.
54.
Kopman AF, Yee PS, Neuman GG: Relationship of
the train-of-four fade ratio to clinical signs and symptoms of residual paralysis
in awake volunteers. Anesthesiology 86:765–771, 1997.
55.
Debaene B, Plaud B, Dilly MP, et al: Residual
paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant
with an intermediate duration of action. Anesthesiology 98:1042–1048, 2003.
56.
Johansen SH, Jorgensen M, Molbeck S: Effect of
tubocurarine on respiratory and nonrespiratory muscle power in man. J Appl Physiol
19:990–994, 1964.
57.
Ali HH, Wilson RS, Savarese JJ, et al: The effect
of tubocurarine on indirectly elicited train-of-four muscle response and respiratory
measurements in humans. Br J Anaesth 47:570–574, 1975.
58.
Viby-Mogensen J, Jorgensen BC, Ording H: Residual
curarization in the recovery room. Anesthesiology 50:539–541, 1979.
59.
Bevan DR, Smith CE, Donati F: Postoperative neuromuscular
blockade: A comparison between atracurium, vecuronium, and pancuronium. Anesthesiology
69:272–276, 1988.
60.
Berg H, Roed J, Viby-Mogensen J, et al: Residual
neuromuscular block is a risk factor for postoperative pulmonary complications.
A prospective, randomised, and blinded study of postoperative pulmonary complications
after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand 41:1095–1103,
1997.
61.
Bovet D: Some aspects of the relationship between
chemical constitution and curare-like activity. An N Y Acad Sci 54:407–437,
1951.
62.
Chestnut RJ, Healy TE, Harper NJ, et al: Suxamethonium—the
relation between dose and response. Anaesthesia 44:14–18, 1989.
63.
Szalados JE, Donati F, Bevan DR: Effect of d-tubocurarine
pretreatment on succinylcholine twitch augmentation and neuromuscular blockade.
Anesth Analg 71:55–59, 1990.
64.
Smith CE, Donati F, Bevan DR: Dose-response curves
for succinylcholine: Single versus cumulative techniques. Anesthesiology 69:338–342,
1988.
65.
Kopman AF, Klewicka MM, Neuman GG: An alternate
method for estimating the dose-response relationships of neuromuscular blocking drugs.
Anesth Analg 90:1191–1197, 2000.
66.
Ferguson A, Bevan DR: Mixed neuromuscular block:
The effect of precurarization. Anaesthesia 36:661–666, 1981.
67.
Curran MJ, Donati F, Bevan DR: Onset and recovery
of atracurium and suxamethonium-induced neuromuscular blockade with simultaneous
train-of-four and single twitch stimulation. Br J Anaesth 59:989–994, 1987.
68.
Mehta MP, Sokoll MD, Gergis SD: Accelerated onset
of non-depolarizing neuromuscular blocking drugs: Pancuronium, atracurium and vecuronium.
A comparison with succinylcholine. Eur J Anaesthesiol 5:15–21, 1988.
69.
Viby-Mogensen J: Correlation of succinylcholine
duration of action with plasma cholinesterase activity in subjects with the genotypically
normal enzyme. Anesthesiology 53:517–520, 1980.
70.
Katz RL, Ryan JF: The neuromuscular effects of
suxamethonium in man. Br J Anaesth 41:381–390, 1969.
71.
Gissen AJ, Katz RL, Karis JH, et al: Neuromuscular
block in man during prolonged arterial infusion with succinylcholine. Anesthesiology
27:242–249, 1966.
72.
Foldes FF, McNall PG, Birch JH: The neuromuscular
activity of succinylmonocholine iodide in man. BMJ 1:967–968, 1954.
73.
Baldwin KA, Forney R Jr: Correlation of plasma
concentration and effects of succinylcholine in dogs. J Forensic Sci 33:470–479,
1988.
74.
Foldes FF, Rendell-Baker L, Birch JH: Causes and
prevention of prolonged apnea with succinylcholine. Anesth Analg 35:609–633,
1956.
75.
Lepage L, Schiele F, Gueguen R, et al: Total cholinesterase
in plasma: Biological variations and reference limits. Clin Chem 31:546–550,
1985.
76.
Kopman AF, Strachovsky G, Lichtenstein L: Prolonged
response to succinylcholine following physostigmine. Anesthesiology 49:142–143,
1978.
77.
Sunew KY, Hicks RG: Effects of neostigmine and
pyridostigmine on duration of succinylcholine action and pseudocholinesterase activity.
Anesthesiology 49:188–191, 1978.
78.
Lindsay PA, Lumley J: Suxamethonium apnoea masked
by tetrahydroaminacrine. Anaesthesia 33:620–622, 1978.
79.
Walts LF, DeAngelis J, Dillon JB: Clinical studies
of the interaction of hexafluorenium and succinylcholine in man. Anesthesiology
33:503–507, 1970.
80.
Baraka A: Hexafluorenium-suxamethonium interaction
in patients with normal versus atypical cholinesterase. Br J Anaesth 47:885–888,
1975.
81.
Kao YJ, Tellez J, Turner DR: Dose-dependent effect
of metoclopramide on cholinesterases and suxamethonium metabolism. Br J Anaesth
65:220–224, 1990.
82.
Woodworth GE, Sears DH, Grove TM, et al: The effect
of cimetidine and ranitidine on the duration of action of succinylcholine. Anesth
Analg 68:295–297, 1989.
83.
Fisher DM, Caldwell JE, Sharma M, et al: The influence
of bambuterol (carbamylated terbutaline) on the duration of action of succinylcholine-induced
paralysis in humans. Anesthesiology 69:757–759, 1988.
84.
Bang U, Viby-Mogensen J, Wiren JE, et al: The
effect of bambuterol (carbamylated terbutaline) on plasma cholinesterase activity
and suxamethonium-induced neuromuscular blockade in genotypically normal patients.
Acta Anaesthesiol Scand 34:596–599, 1990.
85.
Barabas E, Zsigmond EK, Kirkpatrick AF: The inhibitory
effect of esmolol on human plasmacholinesterase. Can Anaesth Soc J 33:332–335,
1986.
86.
Murthy VS, Patel KD, Elangovan RG, et al: Cardiovascular
and neuromuscular effects of esmolol during induction of anesthesia. J Clin Pharmacol
26:351–357, 1986.
87.
Pantuck EJ: Ecothiopate iodide eye drops and prolonged
response to suxamethonium. Br J Anaesth 38:406–407, 1966.
88.
Kalow W, Genest K: A method for the detection
of atypical forms of human serum cholinesterase: Determination of dibucaine numbers.
Can J Med Sci 35:339–346, 1957.
89.
Pantuck EJ: Plasma cholinesterase: Gene and variations.
Anesth Analg 77:380–386, 1993.
90.
Jensen FS, Viby-Mogensen J: Plasma cholinesterase
and abnormal reaction to succinylcholine: Twenty years' experience with the Danish
Cholinesterase Research Unit. Acta Anaesthesiol Scand 39:150–156, 1995.
91.
Primo-Parmo SL, Bartels CF, Wiersema B, et al:
Characterization of 12 silent alleles of the human butyrylcholinesterase (BCHE)
gene. Am J Hum Genet 58:52–64, 1996.
92.
Primo-Parmo SL, Lightstone H, La Du BN: Characterization
of an unstable variant (BChE115D) of human butyrylcholinesterase. Pharmacogenetics
7:27–34, 1997.
93.
Galindo AHF, Davis TB: Succinylcholine and cardiac
excitability. Anesthesiology 23:32–40, 1962.
94.
Goat VA, Feldman SA: The dual action of suxamethonium
on the isolated rabbit heart. Anaesthesia 27:149–153, 1972.
95.
Craythorne NW, Turndorf H, Dripps RD: Changes
in pulse rate and rhythm associated with the use of succinylcholine in anesthetized
patients. Anesthesiology 21:465, 1960.
96.
Leigh MM, McCoy DD: Bradycardia following intravenous
administration of succinylcholine chloride to infants and children. Anesthesiology
18:698–702, 1957.
97.
Stoelting RK, Peterson C: Heart-rate slowing and
junctional rhythm following intravenous succinylcholine with and without intramuscular
atropine preanesthetic medication. Anesth Analg 54:705–709, 1975.
98.
Schoenstadt DA, Whitcher CE: Observations on the
mechanism of succinylcholine-induced cardiac arrhythmias. Anesthesiology 24:358–362,
1963.
99.
Badgwell JM, Cunliffe M, Lerman J: Thiopental
attenuates dysrhythmias in children: Comparison of induction regimens. Tex Med
86:36–38, 1990.
100.
Mathias JA, Evans-Prosser CD, Churchill-Davidson
HC: The role of the non-depolarizing drugs in the prevention of suxamethonium bradycardia.
Br J Anaesth 42:609–613, 1970.
101.
Leiman BC, Katz J, Butler BD: Mechanisms of succinylcholine-induced
arrhythmias in hypoxic or hypoxic: hypercarbic dogs. Anesth Analg 66:1292–1297,
1987.
102.
Nigrovic V, McCullough LS, Wajskol A, et al:
Succinylcholine-induced increases in plasma catecholamine levels in humans. Anesth
Analg 62:627–632, 1983.
103.
Derbyshire DR: Succinylcholine-induced increases
in plasma catecholamine levels in humans. Anesth Analg 63:465–467, 1984.
104.
Derbyshire DR, Chmielewski A, Fell D, et al:
Plasma catecholamine responses to tracheal intubation. Br J Anaesth 55:855–860,
1983.
105.
Roth F, Wuthrich H: The clinical importance of
hyperkalaemia following suxamethonium administration. Br J Anaesth 41:311–316,
1969.
106.
Powell JN, Golby MG: Changes in serum potassium
following suxamethonium in the uraemic rat. Br J Anaesth 42:804, 1970.
107.
Powell JN, Golby M: The pattern of potassium
liberation following a single dose of suxamethonium in normal and uraemic rats.
Br J Anaesth 43:662–668, 1971.
108.
Walton JD, Farman JV: Suxamethonium, potassium
and renal failure. Anaesthesia 28:626–630, 1973.
109.
Miller RD, Way WL, Hamilton WK, et al: Succinylcholineinduced
hyperkalemia in patients with renal failure? Anesthesiology 36:138–141, 1972.
110.
Powell DR, Miller R: The effect of repeated doses
of succinylcholine on serum potassium in patients with renal failure. Anesth Analg
54:746–748, 1975.
111.
Koide M, Waud BE: Serum potassium concentrations
after succinylcholine in patients with renal failure. Anesthesiology 36:142–145,
1972.
112.
Walton JD, Farman JV: Suxamethonium hyperkalaemia
in uraemic neuropathy. Anaesthesia 28:666–668, 1973.
113.
Schwartz DE, Kelly B, Caldwell JE, et al: Succinylcholineinduced
hyperkalemic arrest in a patient with severe metabolic acidosis and exsanguinating
hemorrhage. Anesth Analg 75:291–293, 1992.
114.
Antognini JF, Gronert GA: Succinylcholine causes
profound hyperkalemia in hemorrhagic, acidotic rabbits. Anesth Analg 77:585–588,
1993.
115.
Antognini JF: Splanchnic release of potassium
after hemorrhage and succinylcholine in rabbits. Anesth Analg 78:687–690,
1994.
116.
Kohlschütter B, Baur H, Roth F: Suxamethonium-induced
hyperkalaemia in patients with severe intra-abdominal infections. Br J Anaesth 48:557–562,
1976.
117.
Stevenson PH, Birch AA: Succinylcholine-induced
hyperkalemia in a patient with a closed head injury. Anesthesiology 51:89–90,
1979.
118.
Birch AA Jr, Mitchell GD, Playford GA, et al:
Changes in serum potassium response to succinylcholine following trauma. JAMA 210:490–493,
1969.
119.
Gronert GA, Theye RA: Pathophysiology of hyperkalemia
induced by succinylcholine. Anesthesiology 43:89–99, 1975.
120.
Pandey K, Badola RP, Kumar S: Time course of
intraocular hypertension produced by suxamethonium. Br J Anaesth 44:191–196,
1972.
121.
Indu B, Batra YK, Puri GD, et al: Nifedipine
attenuates the intraocular pressure response to intubation following succinylcholine.
Can J Anaesth 36:269–272, 1989.
122.
Meyers EF, Krupin T, Johnson M, et al: Failure
of nondepolarizing neuromuscular blockers to inhibit succinylcholineinduced increased
intraocular pressure, a controlled study. Anesthesiology 48:149–151, 1978.
123.
Konchigeri HN, Lee YE, Venugopal K: Effect of
pancuronium on intraocular pressure changes induced by succinylcholine. Can Anaesth
Soc J 26:479–481, 1979.
124.
Libonati MM, Leahy JJ, Ellison N: The use of
succinylcholine in open eye surgery. Anesthesiology 62:637–640, 1985.
125.
Joshi C, Bruce DL: Thiopental and succinylcholine:
Action on intraocular pressure. Anesth Analg 54:471–475, 1975.
126.
Pollack AL, McDonald RH, Ai E, et al: Massive
suprachoroidal hemorrhage during pars plana vitrectomy associated with Valsalva maneuver.
Am J Ophthalmol 132:383–387, 2001.
127.
Grennan J: The cardio-oesphageal junction. Br
J Anaesth 33:432, 1961.
128.
Miller RD, Way WL: Inhibition of succinylcholine-induced
increased intragastric pressure by nondepolarizing muscle relaxants and lidocaine.
Anesthesiology 34:185–188, 1971.
129.
Salem MR, Wong AY, Lin YH: The effect of suxamethonium
on the intragastric pressure in infants and children. Br J Anaesth 44:166–170,
1972.
130.
Minton MD, Grosslight K, Stirt JA, et al: Increases
in intracranial pressure from succinylcholine: Prevention by prior nondepolarizing
blockade. Anesthesiology 65:165–169, 1986.
131.
Stirt JA, Grosslight KR, Bedford RF, et al: "Defasciculation"
with metocurine prevents succinylcholine-induced increases in intracranial pressure.
Anesthesiology 67:50–53, 1987.
132.
Brodsky JB, Brock-Utne JG, Samuels SI: Pancuronium
pretreatment and post-succinylcholine myalgias. Anesthesiology 51:259–261,
1979.
133.
Waters DJ, Mapleson WW: Suxamethonium pains:
Hypothesis and observation. Anaesthesia 26:127–141, 1971.
134.
Ryan JF, Kagen LJ, Hyman AI: Myoglobinemia after
a single dose of succinylcholine. N Engl J Med 285:824–827, 1971.
135.
Maddineni VR, Mirakhur RK, Cooper AR: Myalgia
and biochemical changes following suxamethonium after induction of anaesthesia with
thiopentone or propofol. Anaesthesia 48:626–628, 1993.
136.
McLoughlin C, Elliott P, McCarthy G, et al: Muscle
pains and biochemical changes following suxamethonium administration after six pretreatment
regimens. Anaesthesia 47:202–206, 1992.
137.
Demers-Pelletier J, Drolet P, Girard M, et al:
Comparison of rocuronium and d-tubocurarine for
prevention of succinylcholine-induced fasciculations and myalgia. Can J Anaesth
44:1144–1147, 1997.
138.
Naguib M, Farag H, Magbagbeola JA: Effect of
pre-treatment with lysine acetyl salicylate on suxamethonium-induced myalgia. Br
J Anaesth 59:606–610, 1987.
139.
Zahl K, Apfelbaum JL: Muscle pain occurs after
outpatient laparoscopy despite the substitution of vecuronium for succinylcholine.
Anesthesiology 70:408–411, 1989.
140.
Smith I, Ding Y, White PF: Muscle pain after
outpatient laparoscopy—influence of propofol versus thiopental and enflurane.
Anesth Analg 76:1181–1184, 1993.
141.
Leary NP, Ellis FR: Masseteric muscle spasm as
a normal response to suxamethonium. Br J Anaesth 64:488–492, 1990.
142.
Meakin G, Walker RW, Dearlove OR: Myotonic and
neuromuscular blocking effects of increased doses of suxamethonium in infants and
children. Br J Anaesth 65:816–818, 1990.
143.
Littleford JA, Patel LR, Bose D, et al: Masseter
muscle spasm in children: Implications of continuing the triggering anesthetic.
Anesth Analg 72:151–160, 1991.
144.
Habre W, Sims C: Masseter spasm and elevated
creatine kinase after intravenous induction in a child. Anaesth Intensive Care 24:496–499,
1996.
145.
Donlon JV, Newfield P, Sreter F, et al: Implications
of masseter spasm after succinylcholine. Anesthesiology 49:298–301, 1978.
146.
Van der Spek AF, Fang WB, Ashton-Miller JA, et
al: The effects of succinylcholine on mouth opening. Anesthesiology 67:459–465,
1987.
147.
Clarke RSJ: Intubating Conditions and Neuromuscular
Effects following Vecuronium Bromide. Comparison with Suxamethonium Chloride and
Pancuronium Bromide, Clinical Experiences with Norcuron. Amsterdam, Excerpta Medica,
1983.
148.
Heier T, Feiner JR, Lin J, et al: Hemoglobin
desaturation after succinylcholine-induced apnea: A study of the recovery of spontaneous
ventilation in healthy volunteers. Anesthesiology 94:754–759, 2001.
149.
Benumof JL, Dagg R, Benumof R: Critical hemoglobin
desaturation will occur before return to an unparalyzed state following 1 mg/kg intravenous
succinylcholine. Anesthesiology 87:979–982, 1997.
150.
Naguib M, Samarkandi A, Riad W, et al: Optimal
dose of succinylcholine revisited. Anesthesiology 99:1045–1049, 2003.
